REACH and the Safety Data Sheet: documentation duties for research substances

The obligation is not created by the word "research". It is created by classification. Article 31 of the REACH Regulation requires a safety data sheet to be supplied where the substance or mixture meets the criteria for classification as hazardous under the CLP Regulation, where the substance is persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB), or where it has been included in the candidate list under Article 59(1) ^[1]. Many synthetic peptides meet none of those three criteria. For those, the sheet you receive — if you receive one — is a document the supplier compiles voluntarily.

That does not mean there is no documentation to ask for. It means the documentation changes its legal basis: it moves from Article 31 to Article 32, and the judgement about what is sufficient moves from the supplier to you. What follows: which document is owed, in what format, in what language, what "research use" genuinely exempts, and how to read a sheet whose sections half read "no data available".

What triggers the obligation — and what does not

Article 31(1) lists three triggers, and only three ^[1]:

• the substance or mixture is classified as hazardous under Regulation (EC) No 1272/2008 (CLP) ^[3];
• the substance is PBT or vPvB according to the criteria in Annex XIII to REACH;
• the substance is included in the candidate list for authorisation, for any other reason ^[1].

There is a fourth, indirect trigger: for mixtures that are not classified as hazardous but contain hazardous substances above defined concentration thresholds, Article 31(3) obliges the supplier to provide a sheet on request from a professional recipient ^[1]. The request is your move; without it the obligation does not engage. Once it does, the sheet is provided free of charge, on paper or electronically, no later than the first delivery.

MSDS or SDS? The term you ask for matters

"MSDS" (Material Safety Data Sheet) is the old American term, from before OSHA aligned its Hazard Communication Standard with the GHS. In the EU the statutory term is "safety data sheet", and its content is fixed by Annex II to REACH ^[1]. This is not a quibble about vocabulary: a document that arrives titled "MSDS" with eight or nine chapters is not an Annex II sheet and does not discharge an obligation, where one exists.

Annex II was replaced by Regulation (EU) 2020/878, which applies from 1 January 2021; sheets complying with the previous Regulation (EU) 2015/830 were allowed to continue to be provided under a transitional arrangement until 31 December 2022 ^[2]. In practice: any sheet accompanying material placed on the EU market today must follow the 2020/878 format. A sheet whose revision date predates 2021, with no evidence of review, is at best out of date.

The additions made by 2020/878 are specific and easy to check against a sheet in front of you ^[2][4]:

• a unique formula identifier (UFI) in section 1.1, where required;
• explicit statement of specific concentration limits, M-factors and acute toxicity estimates (ATE) in section 3;
• information on endocrine-disrupting properties in sections 2.3, 11 and 12;
• particle characteristics for nanoforms in section 9.

The 16 sections, and which ones you check first

The sixteen sections are fixed, numbered and ordered ^[1]. On receipt of research material, a handful of them decide whether the document is a tool or a decoration.

"Research use": what REACH actually exempts

REACH defines scientific research and development in Article 3(23) as any scientific experimentation, analysis or chemical research carried out under controlled conditions in a volume of less than one tonne per year ^[1]. Below that threshold there is no registration duty — but there would not have been one anyway, since registration begins at one tonne per manufacturer or importer per year. The substantive difference lies elsewhere: the status additionally exempts from certain authorisation duties and from restrictions ^[5].

Above one tonne, the route is Article 9: product and process orientated research and development (PPORD), notified to the European Chemicals Agency, with exemption from registration for five years, extendable by a further five — or by ten where the research concerns medicinal products for human or veterinary use ^[1][5]. The notification is not a formality: the Agency may impose conditions on the exemption.

The point that commercial sources systematically get wrong is a simple one: exemption from registration is not exemption from classification, labelling, packaging or hazard communication. CLP applies to placing on the market regardless of tonnage ^[3]. And a second correction, equally common: the marking "for research use only" is not a legal category in EU chemicals law. It is a commercial designation, and what the research-use-only marking actually signifies is a matter of convention between supplier and buyer rather than of statute. The levers the law recognises are three: classification, quantity, and declared use.

When no sheet is owed: Article 32 and your own risk assessment

When Article 31 does not engage, no gap opens. Article 32 obliges any supplier of a substance for which a safety data sheet is not required to pass to the recipient, free of charge and no later than the first delivery ^[1]:

• the registration number or numbers, if available;
• whether the substance is subject to authorisation, and details of any authorisation granted or refused;
• details of any restriction imposed;
• any other available and relevant information necessary to identify and apply appropriate risk management measures ^[1].

Running in parallel is an obligation that does not depend on the supplier at all. Directive 98/24/EC requires the employer to determine whether hazardous chemical agents are present at the workplace and to assess the risk before work begins ^[6]. In Greece it was transposed by Presidential Decree 338/2001 (Government Gazette 227/A). If the sheet is missing or empty, the written risk assessment is still owed — it is simply drawn up on less data, and that fact is exactly what must be recorded inside it.

What section 11 does not tell you

Section 11 is where a research peptide's sheet usually collapses, and where honesty is worth more than completeness. For newly synthesised or rare peptides there is no published toxicology. When figures nonetheless appear, they almost always come from one of the sources below — and none of them is equivalent to the others.

• Read-across from structurally related substances: an estimate by analogy, not a measurement.
• Computational prediction (QSAR models or other in silico methods): an assumption with a defined applicability domain, which ought to be stated.
• In vitro assays, such as cytotoxicity or genotoxicity screens in cell lines: real data, but for one endpoint only.
• Animal studies, where they exist: they concern the species tested, and translate only under assumptions the sheet itself rarely states.

Human data essentially does not exist for this category of material — the reasons so few research peptides ever reach a human trial are structural rather than accidental — and the wording should not imply otherwise. European Chemicals Agency guidance is clear that section 11 must identify the source and nature of each data point, so that the reader can separate the measured from the estimated ^[4]. A practical rule for assessing a supplier: a sheet that says "no data available" for a substance with no published toxicology is more trustworthy than a sheet presenting a clean toxicological profile while citing no study at all.

Language, versions and archiving

Article 31(5) requires the sheet to be supplied in an official language of the Member State or States where the substance or mixture is placed on the market, unless the Member State provides otherwise ^[1]. For material placed on the Greek market for which a sheet is owed, that means Greek. A supplier who can furnish only an English text does not meet the letter of the provision; a bilingual sheet, Greek and English, is the usual and safer solution for the file.

Paragraph 9 of the same article defines the document's life cycle: the supplier updates it without delay as soon as new information which may affect the risk management measures, or new information on hazards, becomes available, and after an authorisation has been granted or refused or a restriction imposed; the updated version is supplied free of charge to all recipients supplied within the preceding twelve months ^[1]. It is an obligation with a clock on it, and the only way to check it is to know which version you hold.

• Keep the version of the sheet that was current on the date of receipt, not only the current one.
• Tie each sheet to the lot number and the certificate of analysis from the same delivery.
• Record the version number and revision date from section 16 in the goods-in register.
• When an updated version arrives, keep the previous one: if the classification changes, so does what it was reasonable for you to have known at the time.

The Greek frame: who oversees what

In Greece, the national competent authority for the implementation and enforcement of REACH and CLP is the General Chemical State Laboratory (Γενικό Χημείο του Κράτους), a service of the Independent Authority for Public Revenue; that is where implementation questions go and where inspections originate. The National Organisation for Medicines (ΕΟΦ) is a different authority with a different remit: medicinal products. A peptide that is the active substance of an authorised medicine does not stop being a chemical substance, but it is also judged under pharmaceutical law; the two frames apply at once and neither cancels the other. For analytical data, testing laboratories in Greece are accredited by the Hellenic Accreditation System (Ε.ΣΥ.Δ.) against ELOT EN ISO/IEC 17025:2017 ^[7] — and what matters on a certificate of analysis is the scope of accreditation, not a logo.

One last point concerns mixtures rather than pure substances. If the material is a mixture classified as hazardous, Annex VIII to CLP — added by Regulation (EU) 2017/542 — requires a harmonised notification to poison centres and a unique formula identifier ^[8]. The compliance dates were 1 January 2021 for consumer and professional use and 1 January 2024 for industrial use only ^[3]. For industrial-use-only mixtures the identifier may be given in section 1.1 of the safety data sheet instead of on the label — which is why section 1.1 is where you go looking for it.

In sum: a safety data sheet is not a quality certificate and does not replace a certificate of analysis, a separate document read field by field for identity, purity and lot. It is a hazard communication document with a fixed format, a fixed language and a fixed life cycle. Where it is owed, it is requested and checked. Where it is not owed, Article 32 and the laboratory's own risk assessment cover the gap — provided somebody actually writes them.